Abstract

The Scientific Core is designed to successfully recruit and monitor HCV-antibody-negative young injection drug users for HCV infection and to clinically characterize acute infection and identified by testing sera for HCV RNA and seroconversion, and persons with acute infection will be clinically characterized by serial ALT and HCV RNA testing. The infrastructure of the Core is necessary for completion of the first trial of an HCV vaccine in people at risk of HCV infection and will be useful in potential future trials of HCV vaccines. Plasma, serum, and PBMC will be collected and stored in the repository for use in Projects 1-3, as well as for other proposed projects in the Cooperative Research Centers (CRC), including those of Dr.'s Walker, Gale, and Lauer (see LOS provided for their applications). It is also anticipated that these specimens will be shared with NIH- funded investigators outside the CRC. Based on almost 15 years of experience, this Core will be a highly successful component of this CRC.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI088791-10
Application #
9900736
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
10
Fiscal Year
2020
Total Cost
Indirect Cost

  Institution

Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205

  Publications

Kinchen, Valerie J; Cox, Andrea L; Bailey, Justin R (2018) Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine? Trends Microbiol 26:854-864
Esmaeili, Aryan; Mirzazadeh, Ali; Morris, Meghan D et al. (2018) The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 Collaborative. Clin Infect Dis 66:20-28
Kinchen, Valerie J; Zahid, Muhammad N; Flyak, Andrew I et al. (2018) Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection. Cell Host Microbe 24:717-730.e5
Kinchen, Valerie J; Bailey, Justin R (2018) Defining Breadth of Hepatitis C Virus Neutralization. Front Immunol 9:1703
Rose, Rebecca; Lamers, Susanna L; Massaccesi, Guido et al. (2018) Complex patterns of Hepatitis-C virus longitudinal clustering in a high-risk population. Infect Genet Evol 58:77-82
Ke, Ruian; Li, Hui; Wang, Shuyi et al. (2018) Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence. Proc Natl Acad Sci U S A 115:E7139-E7148
Bailey, Justin R; Barnes, Eleanor; Cox, Andrea L (2018) Approaches, Progress, and Challenges to Hepatitis C Vaccine Development. Gastroenterology :
Mankowski, Madeleine C; Kinchen, Valerie J; Wasilewski, Lisa N et al. (2018) Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. Proc Natl Acad Sci U S A 115:E82-E91
Morris, Meghan D; Shiboski, Stephen; Bruneau, Julie et al. (2017) Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration. Clin Infect Dis 64:860-869
Vergara, C; Thio, C; Latanich, R et al. (2017) Genetic basis for variation in plasma IL-18 levels in persons with chronic hepatitis C virus and human immunodeficiency virus-1 infections. Genes Immun 18:82-87

Showing the most recent 10 out of 59 publications